Sherbrooke Park Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Sherbrooke Park Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-566	Closed	-$297K	–	690
2025 Q2	$297K	Sell	566 -32	-5%	-$17.9K	0.13%	309
2025 Q1	$379K	Sell	598 -1,406	-70%	-$967K	0.18%	216
2024 Q4	$1.43M	Buy	+2,004	New	+$1.68M	0.46%	14
2024 Q1	–	Sell	-714	Closed	-$627K	–	974
2023 Q4	$627K	Buy	714 +267	+60%	+$220K	0.29%	120
2023 Q3	$368K	Buy	+447	New	+$351K	0.12%	300
2023 Q1	–	Sell	-500	Closed	-$361K	–	299
2022 Q4	$361K	Buy	+500	New	+$369K	0.26%	171

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sherbrooke Park Advisers's REGN Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 566 shares — an estimated $297K sold.

Sherbrooke Park Advisers first reported a position in REGN in Q4 2022 and held it in 6 quarters. The position peaked at $1.43M in Q4 2024. 1,245 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Sherbrooke Park Advisers reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Sherbrooke Park Advisers sold 566 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $297K.
Sherbrooke Park Advisers first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 6 quarters.
Sherbrooke Park Advisers's Regeneron Pharmaceuticals position peaked at $1.43M in Q4 2024.
1,245 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.